Ozenoxacin

Class: Quinolone

Spectrum of activity:	Gram-positive
Details of activity:	Acute bacterial skin and skin structure infections
Description:	Preclinical In Vitro and In Vivo Absorption Evaluation Of Ozenoxacin (GF-001001-00): A Novel Topical Non-Fluorinated Quinolone. By: Santos, B.; Albet, C.; Orriols, A.; et al.
Institute where first reported:	Ferrer Pharma, Spain
Year first mentioned:	2007
Highest developmental phase:	Approved by FDA in 2017
Development status:	Approved

Chemical structure(s):
Canonical SMILES:	CC1=CC(=CN=C1NC)C2=CC=C3C(=C2C)N(C=C(C3=O)C(=O)O)C4CC4
Isomeric SMILES:	CC1=CC(=CN=C1NC)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)C
InChI:	InChI=1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27)
InChI Key:	XPIJWUTXQAGSLK-UHFFFAOYSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/9863827

External links:
Guide to Pharmacology:	ozenoxacin
Main Source:	http://productos.ferrer.com/innovation/key-development-projects
Citation:	http://aac.asm.org/content/57/12/6389.full